Table 3.
Treatment received for COVID-19 in the study population, stratified by occurrence of pulmonary embolism
| All (n = 689) | No PE (n = 637) | PE (n = 52) | p value | |
|---|---|---|---|---|
| Medical therapy | ||||
| Lopivanir/ritonavir | 184 (26.9) | 169 (26.7) | 15 (29.4) | 0.67 |
| Darunavir/ritonavir | 168 (24.6) | 148 (23.4) | 20 (39.2) | 0.01 |
| Remdesivir | 5 (0.7) | 4 (0.6) | 1 (2.0) | 0.28 |
| Corticosteroid | 341 (49.9) | 310 (49.0) | 31 (60.8) | 0.10 |
| Tocilizumab | 79 (11.5) | 64 (10.1) | 15 (29.4) | < 0.001 |
| Hydroxychloroquine | 574 (83.9) | 527 (83.3) | 47 (92.2) | 0.10 |
| Ventilation support | ||||
| Oxygen with FiO2 ≥ 50% | 375 (55.7) | 338 (54.3) | 37 (74) | 0.007 |
| Non-invasive ventilation | 298 (43.6) | 264 (41.8) | 34 (65.4) | < 0.001 |
| Intubation | 108 (15.8) | 88 (13.9) | 20 (38.5) | < 0.001 |
Data are shown as count (%)
Note that oxygen was given with a FiO2 ≥ 50% to both non-ventilated and ventilated patients
sc subcutaneous, iv intravenous, FiO2 fraction of inspired oxygen